Title:
tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. | Journal:
Antimicrobial agents and chemotherapy. 2004 Jun;48(6):1953-9 | Authors:
Maki H, McCallum N, Bischoff M, Wada A, Berger-Bächi B. | Abstract:
The experimental deletion of the tcaRAB region has been shown to increase teicoplanin resistance in Staphylococcus aureus. By sequential genetic complementation of a tcaRAB mutant, we identified tcaA as the key gene within tcaRAB that is responsible for changes in glycopeptide resistance levels. Northern blot analysis of the tcaRAB region showed that the tcaA gene is expressed only weakly over the growth cycle and is strongly inducible by teicoplanin. Among some clinical isolates tested, glycopeptide-intermediate-resistant (GISA) strains Michigan and SA137/93G were found to have truncated tcaA genes. While the former carries a nucleotide insertion that creates a premature stop codon, the latter was found to harbor an IS256 insertion. Complementation of these two GISA strains with a functional tcaA allele reduced their levels of teicoplanin and vancomycin resistance five- to eightfold and twofold, respectively. The data presented here indicate that inactivation of tcaA contributes to and plays a relevant role in glycopeptide resistance in S. aureus clinical isolates. | | See full PubMed entry: http://www.ncbi.nlm.nih.gov/pubmed/15155184 |
|
BRAID